Healthcare Professionals

About ROMA™

Know the right treatment path.

The path to optimal
patient outcomes begins
with CA125 + HE4.

ROMA, the combination of CA125 + HE4 tests, along with menopausal status, is used to help determine the likelihood of finding a malignancy on surgery in women who present with adnexal mass. Risk stratification helps ensure optimal patient care by promoting the triage of patients at high risk of ovarian malignancy to tertiary care centers with multidisciplinary teams that specialize in ovarian cancer.

In a recent study, ROMA was evaluated in 472 women with adnexal mass who were initially assessed by generalist Ob/Gyns and primary care physicians and subsequently underwent surgery. ROMA correctly identified 94% of women with an epithelial ovarian cancer as high risk. These patients can be referred to specialized gynecologic oncologists for optimal care. At the same time, 75% of patients with benign disease was correctly identified and could undergo treatment by their gynecologist in the community.8

In summary, the CA125 + HE4 combination accurately determines risk of malignancy:8

  • Many markers have been studied, but the CA125 + HE4 combination has proven to be a more accurate predictor of malignant disease than either marker alone7
  • Patients classified as being at increased risk for ovarian cancer can be referred to a gynecologic oncologist (GYN/ONC) for optimal care9,11
  • In a prospective multi-center study, the combination assay yielded a sensitivity of 94%, with a fixed specificity of 75%8

OBG Management LogoRead "In women who have a pelvic mass
Have you tried this new ovarian Ca biomarker?"

recently published in OBG Management.